Editas Medicine (NASDAQ:EDIT) Raised to Hold at Wall Street Zen

Editas Medicine (NASDAQ:EDIT) was upgraded by analysts at Wall Street Zen from a “sell” rating to a “hold” rating in a research note issued to investors on Saturday.

Several other brokerages have also recently commented on EDIT. Weiss Ratings reiterated a “sell (e+)” rating on shares of Editas Medicine in a research report on Friday, July 17th. TD Cowen restated a “buy” rating on shares of Editas Medicine in a report on Wednesday, May 27th. Finally, Chardan Capital raised their price objective on shares of Editas Medicine from $3.50 to $4.00 and gave the company a “buy” rating in a research note on Tuesday, May 5th. Five analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat.com, Editas Medicine has an average rating of “Moderate Buy” and an average target price of $5.40.

Editas Medicine Price Performance

Editas Medicine stock opened at $2.88 on Friday. The business’s 50-day simple moving average is $2.90 and its 200 day simple moving average is $2.64. The stock has a market cap of $281.98 million, a price-to-earnings ratio of -3.84 and a beta of 2.14. Editas Medicine has a 12-month low of $1.66 and a 12-month high of $4.54.

Editas Medicine (NASDAQ:EDIT) last announced its quarterly earnings data on Wednesday, August 5th. The company reported ($0.15) EPS for the quarter, topping analysts’ consensus estimates of ($0.27) by $0.12. Editas Medicine had a negative return on equity of 196.63% and a negative net margin of 157.32%.The firm had revenue of $11.89 million during the quarter, compared to analyst estimates of $2.85 million. As a group, sell-side analysts expect that Editas Medicine will post -0.93 EPS for the current year.

Insider Transactions at Editas Medicine

In other news, CEO Gilmore Neil O’neill sold 15,380 shares of the business’s stock in a transaction dated Wednesday, June 3rd. The stock was sold at an average price of $2.70, for a total transaction of $41,526.00. Following the completion of the transaction, the chief executive officer directly owned 248,313 shares in the company, valued at approximately $670,445.10. The trade was a 5.83% decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 21,503 shares of company stock worth $57,910 in the last quarter. 3.10% of the stock is currently owned by company insiders.

Institutional Trading of Editas Medicine

Hedge funds have recently modified their holdings of the company. Captrust Financial Advisors acquired a new stake in Editas Medicine in the second quarter worth $26,000. StoneX Group Inc. acquired a new position in shares of Editas Medicine in the 4th quarter valued at $33,000. Abel Hall LLC acquired a new position in shares of Editas Medicine in the 1st quarter valued at $36,000. Victory Capital Management Inc. bought a new stake in shares of Editas Medicine in the 3rd quarter valued at $36,000. Finally, Pallas Capital Advisors LLC bought a new stake in shares of Editas Medicine in the 2nd quarter valued at $38,000. 71.90% of the stock is currently owned by institutional investors and hedge funds.

Editas Medicine News Roundup

Here are the key news stories impacting Editas Medicine this week:

• Positive Sentiment: HC Wainwright raised multiple earnings forecasts. The firm improved its FY2026 EPS estimate to a loss of $0.66 from $1.04 and its FY2027 estimate to a loss of $0.70 from $1.15. Quarterly estimates were also raised, including Q3 2026 to a loss of $0.20 from $0.33 and Q4 2026 to a loss of $0.08 from $0.13. These revisions suggest analysts expect Editas Medicine’s losses to narrow more quickly than previously anticipated. HC Wainwright earnings estimates
• Positive Sentiment: Forecasts for 2027 also improved. HC Wainwright raised its estimates for the first three quarters of 2027, with Q1 and Q2 losses now projected at $0.20 per share and Q3 at $0.21, compared with prior estimates of $0.33 and $0.34 for the quarters revised in the reports. The more favorable outlook could improve investor sentiment toward the gene-editing company’s cost and revenue trajectory. Editas Medicine analyst estimates
• Neutral Sentiment: Wall Street Zen upgraded Editas Medicine to “Hold.” The rating indicates a neutral stance rather than a bullish recommendation, suggesting the shares may be fairly valued while investors await additional clinical, commercial, or financial progress. Editas Medicine upgraded to Hold
• Negative Sentiment: Editas is still expected to remain unprofitable. Even after the revisions, HC Wainwright forecasts losses through 2027, and the broader current-year consensus remains a loss of approximately $1.03 per share. Investors should therefore view the estimate increases as a reduction in expected losses, not evidence that the company has reached profitability.

About Editas Medicine

Editas Medicine is a clinical-stage biotechnology company focused on translating the power of gene editing into a new class of transformative genomic medicines. Founded in 2013 and headquartered in Cambridge, Massachusetts, the company leverages proprietary CRISPR/Cas9 and CRISPR/Cas12a (Cpf1) platforms to develop therapies aimed at correcting disease-causing genetic mutations. Editas Medicine’s research and development efforts span multiple therapeutic areas, including inherited retinal diseases, hemoglobinopathies, and oncology.

The company’s pipeline includes EDIT-101, a lead candidate designed to treat Leber congenital amaurosis type 10 (LCA10), which has entered early-stage clinical trials, and EDIT-301, targeting sickle cell disease and β-thalassemia using an ex vivo editing approach.